V. L. Serebruany (1)
(1) HeartDrug™ Research Laboratories, Johns Hopkins University, Towson, Maryland, USA
The PLATO trial revealed excess all-cause (4.5%) and vascular (4.0%) mortality after experimental pyrimidine, ticagrelor, and even higher death rates (5.9% and 5.1%, respectively) after clopidogrel, which have never been seen in any previous acute coronary syndrome (ACS) trial. The Food and Drug Administration (FDA) conducted, and recently released the ticagrelor review outlining some paradoxical mortality patterns in PLATO, including the existence of alive patient, who initially was reported dead. The drug was recently approved in Europe, but repeatedly delayed in the USA. The objective of this viewpoint article was to evaluate extremely high death rates in PLATO by scrutinising FDA-released evidence, and comparing mortality patterns in recent ACS trials. These data were first presented as the analytical report submitted to the FDA on October 26, 2010. The available evidence suggest that mortality rates in PLATO, so as death benefit of ticagrelor over clopidogrel are extreme, despite incomplete follow-up, short duration of the trial, frequent preloading with clopidogrel, and gross mismatch between conventional average myocardial infarction rates but disproportionally frequent vascular fatalities, and heavily imbalanced sepsis-related deaths. In contrast to the overall PLATO results, the deaths rates in the USA were much lower (3.2% vs. 3.8%) not only favouring clopidogrel, but more importanly matching very well with identical rates in TRITON (3.2%), and one-year ACUITY (3.6%-3.9%) fatalities. Since the «play of chance» cannot explain these discrepancies due to excess death rates in both PLATO arms, and considering that study sponsor self-monitored sites in most countries, but not in the USA, the mortality data are questionable, and should be independently virified. It was concluded that excess mortality rates and delayed timing of the benefit onset in PLATO do not match with any recent ACS trial, and do not look natural. Reevaluation of the survival, especially driven from the several high-volume sponsor monitored sites in Eastern Europe may reveal discrepancies between those reported in PLATO and actual vital records. Future practice of self monitoring in pivotal indication-seeking clinical trials should be completely banned.
Clinical Trial, Mortality, outcomes, ticagrelor, site monitoring
V. L. Serebruany (1)
Thromb Haemost 2010 103 2: 259-261
R. Grütter (1) , W. Fierz (2)
Methods Inf Med 1999 38 3: 154-157
J. Wöhrle1*, T. Nusser1*, B. J. Krause4*, M. Kochs1, T. Habig1, F. M. Mottaghy3, H. A. Kestler2, V. Hombach1, S. N. Reske3
Nuklearmedizin 2007 46 5: 185-191
The May 2013 issue of Thrombosis and Haemostasis 109.5 is a clinically relevant 'state of the art'...
Starting with the April 2013 issue of "Thrombosis and Haemostasis" TH109.4, the ESC...
The March 2013 issue TH 109.3 of Thrombosis and Haemostasis is a Theme Issue by Guest Editors...